ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.
The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
ExpreS2ion Biotechnologies will release its Q1 results on 16 May 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies’ CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event.
After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.
ExpreS2ion Biotechnologies today announced, that AdaptVac which ExpreS2ion owns 34% of, has received EUR 10 million in milestone payment from Bavarian Nordic.
Together with ExpreS2ion Biotechnologies CEO Bent Frandsen, we took a look at 2023's main achievements and challenges as well as the foundation this has given the company. We also touched upon 2024, focusing on what investors should look out for as the main potential achievements.
The strong finish to 2023 didn’t last into 2024 as Biotech and Life Science stocks moved sideways the last month and were unable to keep pace with the general stock market, which managed to climb to new record highs.
ExpreS2ion Biotechnologies will release its 2023 year-end results on 8 February 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies’ CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event.
At the event CEO Bent Frandsen presented the company's ExpreS2-platform and Adaptvac’s VLP technology. This unique technology platform is used for several projects in the company’s broad pipeline.